New chemo cocktail aims to boost stem cell transplant success in blood cancers

NCT ID NCT02250937

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can improve outcomes for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls 116 adults aged 18-70 who have a matched donor. The goal is to see if this approach helps destroy cancer cells more effectively and leads to longer survival without the disease returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (venetoclax, busulfan, cladribine, fludarabine) followed by donor stem cell transplant
What this could lead to: If successful, this approach could improve long-term survival and reduce relapse for people with AML or MDS undergoing a donor stem cell transplant.
What could go wrong: This is a mid-stage trial with only 116 participants, so results may not apply to everyone. The intense chemo regimen carries risks like infection, organ damage, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.